SCHEMBL5438403

SCHEMBL5438403

O=c1ccc(-c2ccc(Cl)cc2)cn1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 5/20 0.54
MKNK2 Q9HBH9 5/20 0.54
BRD4 O60885 2/20 0.53
PTGDR2 Q9Y5Y4 2/20 0.52
ALDH1A1 P00352 3/20 0.51
CREBBP Q92793 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MAPT P10636 2/20 0.49
BRD2 P25440 1/20 0.49
BRD3 Q15059 1/20 0.49
BRDT Q58F21 1/20 0.49
OPRK1 P41145 1/20 0.48
TP53 P04637 1/20 0.48
HRH3 Q9Y5N1 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
CYP1A2 P05177 1/20 0.45
SDHB P21912 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5433212 0.95 ALDH1A1 (0.53) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5445259 0.91 MKNK1 (0.58) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5448923 0.90 MKNK1 (0.47) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5437022 0.86 MKNK1 (0.62) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL27772274 0.86 MAPT (0.63) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5439773 0.85 CREBBP (0.53) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5435554 0.85 PTGDR2 (0.54) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5437566 0.85 BRD4 (0.59) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5437260 0.84 MKNK1 (0.60) MKNK1MKNK2BRD4PTGDR2ALDH1A1
SCHEMBL5195278 0.84 FABP6 (0.47) MKNK1MKNK2PTGDR2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799646-B1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2014-12-10 EP claimed
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US claimed
EP-1799646-B1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2014-12-10 EP disclosed
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 MKNK1 2293/4885MKNK2 1366/4885BRD4 1456/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 MKNK1 1868/4885MKNK2 1100/4885BRD4 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.